Moderna Announces New Data from mRNA Therapeutics Studies to be Presented at ESMO Congress 2025
Reuters
Jul 28
<a href="https://laohu8.com/S/MRNA">Moderna</a> Announces New Data from mRNA <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Studies to be Presented at ESMO Congress 2025
Moderna Inc. has announced that data from three abstracts on its investigational mRNA therapeutics will be presented at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, taking place from October 17-21, 2025. The presentations include a mini oral presentation on mRNA-4359, Moderna's investigational mRNA-based therapy aimed at eliciting T-cell immune responses against tumor and immunosuppressive cells. Additionally, there will be two poster presentations on intismeran autogene (V940/mRNA-4157), a therapy jointly developed by Moderna and Merck. The presentations cover various studies, including a trial of mRNA-4359 in checkpoint inhibitor-resistant/refractory melanoma, and two phase 2 studies of intismeran autogene for high-risk non-muscle-invasive bladder cancer and as a first-line therapy for advanced melanoma. The results of these studies will be presented at the congress.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1053370) on July 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.